Selected key takeaway from our 2026 Annual Conference: BTOG 2026 Doctor of the Year Award presented by Tom Newsom-Davis. Full recordings and presentations available to members on our website. #LCSM #lungcancer
@btog.bsky.social
@btog.bsky.socialSelected key takeaway from our 2026 Annual Conference: BTOG 2026 Doctor of the Year Award presented by Tom Newsom-Davis. Full recordings and presentations available to members on our website. #LCSM #lungcancer
@btog.bsky.socialSelected key takeaway from our 2026 Annual Conference: BTOG 2026 Nurse of the Year Award presented by Tom Newsom-Davis. Full recordings and presentations available to members on our website. #LCSM #lungcancer
@glcc01.bsky.socialAt our Annual Meeting in Seoul, Karen Clayton of Lung Cancer Nursing UK spoke to the role of lung cancer nurse specialists. They provide more than clinical care, supporting patients and carers emotionally, psychologically and practically.
#LungCancer #CancerCare #PatientAdvocacy #HealthcareEquity
@lungcancereurope.bsky.socialMissed our #SCLC webinar, or want to revisit the discussion?
Watch the replay of Fast diagnosis, fragmented support: living with small-cell #lungcancer in Europe.
We’ve also added answers to audience Qs, including those we couldn’t cover live.
@vcclibrary.bsky.socialImproved quality of life and prolonged survival with add-on homeopathic treatment in patients with non-small cell #LungCancer: a prospective, randomized, placebo-controlled, double-blind, three-arm, multicenter study. link.springer.com/article/10.1...
@glcc01.bsky.socialGreetings from Seoul 🇰🇷 for the GLCC Annual Members’ Meeting. Bo Aldige shared highlights from 25 years of GLCC’s work and thanked Roy Castle Lung Cancer Foundation for secretariat support. We’re now 44 members across 32 countries. #lungcancer #lungcancerawareness #lungcanceradvocacy
@oae-evcna.bsky.social🧬How do #EVs shape the tumor microenvironment?
This study highlights exosomal LYPLAL1-DT as a mediator of bidirectional communication between small cell #lungcancer and endothelial cells, promoting tumor progression and angiogenesis. 🧬
www.oaepublish.com/articles/evc...
@goetzjacky.bsky.social
@btog.bsky.socialKey takeaway from our 2026 Conference: Malnutrition incidence in lung cancer patients at NCCC outpatient clinic. Full details for members. #LCSM #lungcancer
@thecancersurvivorsclub.comEncouraging lung cancer results: Imdelltra plus Imfinzi significantly improved overall survival in a late-stage trial for extensive-stage small-cell lung cancer.
@bryanchristian.bsky.socialScientists make concerning discovery about lung cancer and microplastics
www.independent.co.uk/news/health/...
#Health #Lungs #Cancer #LungCancer #Microplastics #PlasticPollution #Study
@lcrf.orgWhen Glenna’s initial #LungCancer treatment failed, biomarker testing gave her doctors the key to a targeted treatment. Today, she has no evidence of disease.
In 2023 – when Glenna was diagnosed – only 2 treatments were approved for HER2+ NSCLC. Now, thanks to research, there are 4. LCRF.org/fall26
@ccsresearch.bsky.social#LungCancer often arises in narrow, fragile spaces deep in the lungs. These tumours can be hard to biopsy – so Chukwudozie Ubosi is developing a tiny robotic device made of soft materials. Using AI-assisted magnetic steering to navigate the lung, the robot will enable easier, safer #cancer biopsies.
@ccsresearch.bsky.socialWildfire smoke exposure is linked to higher #LungCancer risk and lower survival rates. Kenneth Ofori-Amanfo is studying how lung cells react to smoke and how this contributes to #cancer risk. The work could eventually lead to better prevention and new targeted treatments for people with lung cancer.
@oncoalert.bsky.socialFDA News🇺🇸 Sevabertinib Approved in Locally Advanced #NSCLC #LungCancer
On September 9, 2026, the FDA granted accelerated approval to sevabertinib (Hyrnuo) for adults with locally advanced or metastatic non-squamous NSCLC harboring HER2 (ERBB2) TKD activating mutations
@lungcancereurope.bsky.socialThank you @europeanrespsoc.bsky.social for an excellent #ERSCongress2026 in Barcelona.
We presented 2 abstracts, contributed to discussions on #lungcancer & made new connections across respiratory health.
Read our round-up:
lungcancereurope.eu/news/lung-ca...
@alkpositiveuk.bsky.socialScotland has confirmed routine NHS access to lorlatinib after previous ALK+ lung cancer treatment.
It had been available on an interim basis since 2020. Following reassessment and further evidence, that access is now routine.
@healthcare-europe.bsky.social🫁 People with #lungcancer are more likely to have #microplastics in their lungs and to have larger quantities of microplastics in their lungs, according to new research from 🇮🇪 @ucdmedicine.bsky.social, presented at the @europeanrespsoc.bsky.social's #ERSCongress.
@btog.bsky.socialKey takeaway from our 2026 Annual Conference: Lung cancer in never smokers at Guy's Cancer Centre by Alexandra Holdich. Full recordings available to members. #LCSM #lungcancer
@lungcancereurope.bsky.socialFrom today’s #ERSCongress2026 poster session: SCLC survey.
❌ 19/37 were offered no support
🩺 24/37 reported doctor-led decisions
🧪 1/37 reported clinical trial discussions
People with #LungCancer must be part of the conversation.
